Inflamazione sistemica e tossicità specifiche CAR-T come principali driver della mortalità non-rilassante: analisi dallo studio osservazionale prospettico CART-SIE italiano.

BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy has revolutionized outcomes in relapsed/refractory lymphomas, yet nonrelapse mortality (NRM) has emerged as a notable concern, with older age and infections identified as major determinants of NRM in real-life studies. OBJECTIVE: The aim of the present study was to describe the rate and causes of NRM after CAR-T cells and identify risk factors. STUDY DESIGN: Within the framework of the prospective, multicenter, observational CART‑SIE study, we analyzed causes and determinants of NRM in a large real-world cohort of lymphoma patients receiving CAR‑T cells from 2019 to 2025. Associations between NRM and clinical or biological factors